Over the next 10 years, Roche will invest 3 billion Swiss francs in the construction of a new research and development centre for around 1,900 employees, in a state-of-the-art office building for up to 1,700 employees, in upgrading infrastructure, and in renovating the historic office building designed by Otto R. Salvisberg.
A hedge fund run by a famed investor has taken a large stake in Amgen and now wants the biotech...
A Spanish court has upheld an appeal by a German pharmaceutical company, ditching a previous...
First, CVS Health pulled tobacco from its store shelves. Now, it plans to make some customers think twice about filling prescriptions at other stores that still sell smokes. The nation's second-largest drugstore chain is developing a new tobacco-free pharmacy network for clients of its Caremark pharmacy benefits management business.
AbbVie is walking away from its proposed $55 billion takeover bid of Shire and has agreed to pay the rival drugmaker a $1.64 billion breakup fee. The two companies said the deal was off following the decision last week by AbbVie's board to withdraw support from the proposed acquisition.
NewLink said it will get $150M upfront from Genentech, and could receive more than $1B in payments based on milestones, as well as royalties if the drug is approved. The drug, now called NLG919, is in early-stage clinical testing.
The European Union committed itself to step up efforts toward getting 1 billion euros ($1.27 billion) in aid to fight Ebola in West Africa and rejected the idea of halting direct flights coming from the region.
Canadian Law Professor Urges Country to Cancel Ebola Vaccine License with NewLink, Transfer Rights to Bigger CompanyOctober 20, 2014 1:57 pm | by Helen Branswell, The Canadian Press | News | Comments
A prominent law professor is urging the federal government to terminate an American company's licence for a Canadian-made Ebola vaccine. The company, NewLink Genetics, doesn't have the capacity to develop the much-needed vaccine, argues Amir Attaran, a professor of law and population health at the University of Ottawa.
Valeant Pharmaceuticals said that its strong third-quarter results and a higher growth forecast give it ammunition to win over reluctant takeover target Botox maker Allergan with an increased bid at the appropriate time.
Business World Columnist Holman Jenkins Jr. on what’s behind AbbVie’s decision not to merge with Dublin-based Shire.
China has donated $6 million to help stave off food shortages in the three African countries worst affected by the Ebola virus, the World Food Program announced Monday, part of Beijing's growing assistance to a continent where its companies have become major investors.
Aduro Expands Collaboration with Johnson & Johnson Innovation and Janssen for Lung Cancer ImmunotherapiesOctober 17, 2014 8:40 am | News | Comments
Under the agreement, facilitated by the Johnson & Johnson Innovation center in California, Aduro will receive a $30M up-front payment and is eligible to receive significant development, regulatory and commercialization milestone payments up to a potential total of $817M.
Nuvo Research Inc. has completed the sale of its PENNSAID 2% U.S. sales and marketing rights to Horizon Pharma for a cash payment of US$45 million (CDN$50 million) which was payable on closing.
Shares of Sarepta Therapeutics jumped 11 percent before the opening bell Friday after the drug developer said its potential Ebola treatment generated no safety concerns in early-stage human testing.
The development of a vaccine to prevent Ebola virus disease will be accelerated with support from the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR).
Eli Lilly and Company has announced plans to conclude production and pursue a sale of one of its three manufacturing plants in Puerto Rico. The manufacturing site, located in Guayama, Puerto Rico, will remain in operation until the end of 2015.
Roche Holding AG posted flat sales for the first nine months of 2014, but said Thursday the results show strong demand for its cancer drugs and emerging new products.
AbbVie's board is telling shareholders to vote against its own $55 billion takeover bid for the Irish drugmaker Shire after the U.S. made reincorporating overseas a less lucrative tax maneuver.
The Supreme Court seems divided as it considers a high-stakes patent dispute between rival pharmaceutical companies over the world's best-selling multiple sclerosis treatment.
Since 2011 I have postulated that pharma needs a “creative destructionist” for its manufacturing technology innovations to get out from its archaic “quality by analysis” methods to “quality from the get go methods”. Current practices have cost patients billions in excessive costs. Generally most of the “creative destructionists” are from outside the industry, McLaren could be the one for the pharma and the chemical industry.
Shire wants AbbVie to stick with its roughly $55 billion acquisition bid, and it is reminding its U.S. counterpart of the hefty breakup fee it will receive if things don't work out.
Sucampo Pharmaceuticals has announced that it signed an amendment to the existing collaboration and license agreement covering the United States and Canada for AMITIZA with Takeda Pharmaceutical Company.
Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® and IMBRUVICA® in Non-Hodgkin LymphomaOctober 14, 2014 8:48 am | News | Comments
The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).
Just as their economies had begun to recover from the man-made horror of coups and civil war, the West African nations of Guinea, Liberia and Sierra Leone have been knocked back down by a terrifying force of nature: the Ebola virus.
Finance Minister Michael Noonan and Public Expenditure Minister Brendan Howlin are unveiling a 2015 budget Tuesday expected to contain around 1 billion euros ($1.3 billion) in income tax breaks and spending increases, ending a seven-budget run that slashed 30 billion euros from the economy.
Johnson & Johnson has reported third-quarter earnings of $4.75 billion. The results topped Wall Street expectations. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of $1.42 per share.
Endo International’s $2.6 billion purchase of Auxilium Pharmaceuticals complements Endo’s urology and male health portfolio, and the company intends to leverage its resources to optimize and drive increased adoption of three key Auxilium drugs, according to an analyst with research and consulting firm GlobalData.
The presidents of three Ebola-stricken West African nations made urgent pleas for money, doctors and hospital beds Thursday and representatives of nations gathered for a World Bank meeting promised to send more aid quickly.
- Page 1